✦ LIBER ✦
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer
✍ Scribed by Heigener, David F.; von Pawel, Joachim; Eschbach, Corinna; Brune, Andreas; Schmittel, Alexander; Schmelter, Thomas; Reck, Martin; Fischer, Jürgen R.
- Book ID
- 123132202
- Publisher
- Elsevier Science
- Year
- 2013
- Tongue
- English
- Weight
- 316 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.